The Starpharma (ASX: SPL) share price surges on Vietnam launch

The Starpharma Holdings Limited (ASX: SPL) share price is racing ahead this morning after confirming its antiviral nasal spray will …

| More on:
Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies

Image source: Getty Images

The Starpharma Holdings Limited (ASX: SPL) share price is racing ahead this morning after confirming its antiviral nasal spray will be launched in Vietnam this week.

The biotech registered its VIRALEZE spray for sale in the Asian country. It recently signed initial distribution agreements to supply 100,000 units and said it is finalising a contract for ongoing supply of the product.

The Starpharma share price jumped 6.5% to $1.16 at the time of writing when the  S&P/ASX 200 Index (Index:^AXJO) dipped 0.3%.

Vietnam boost for the Starpharma share price

The spray is a broad-spectrum antiviral nasal spray that contains Starpharma’s SPL7013 innovation. Tests have shown that SPL7013 caused the inactivation of more than 99.9% of the Delta COVID-19 mutation.

The initial distribution agreements were signed with Healthco Australia  Pty  Ltd and Vietnam-based Truong Bao Land International Investment  Company  Limited  (TBL).  TBL will also distribute VIRALEZE via its local medical distribution networks.

Starpharma share price breathing easier

This development couldn’t have come at a better time for embattled shareholders. The Starpharma share price has slumped by more than 20% this calendar year. Even with today’s rally, it is still trading close to an 18-month low.

However, the emergence of the Omicron mutation could put COVID-linked ASX shares back into investors’ good books.

From Delta to Omicron

Starpharma trying to capitalise on this by hinting that VIRALEZE could lower the risk of mutations too.

It noted that the mechanism of action meant that mutations of the spike protein that make SARS-CoV-2 more infectious appear to make the virus more susceptible to trapping and blocking by SPL7013.

“We are excited to see the product launched in Vietnam this week,” said Jackie  Fairley,  Starpharma’s chief executive.

“This registration, the first in South East Asia, builds upon existing submissions as well as registrations already achieved in Europe, India and New Zealand, and we are expediting further regulatory submissions in multiple regions and countries.”

Other ASX shares of note

The Starpharma share price isn’t the only one in the sector that is making gains. The IDT Australia Limited (ASX: IDT) share price gained 0.8% to 61.5 cents and the CSL Limited (ASX: CSL) share price added 0.9% to $309.53.

IDT is the first in Australia to develop a manufacturing capability for mRNA vaccines.

The IDT share price jumped by nearly three-fold in 2021 while the CSL share price gained a little over 8%.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Motley Fool contributor Brendon Lau owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. and Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Top 10 - asx shares today
Share Market News

Here are the top 10 ASX shares today

Today, the S&P/ASX 200 Index (ASX: XJO) fought back against the selling pressure throughout the day to finish in the green. …

Read more »

The word inflation written with a ticking time bomb.
Share Market News

Why is it when Jerome Powell sneezes, the ASX 200 catches a cold?

Key points The ASX 200 took a hit following comments from the United States Federal Reserve chair Jerome Powell Expectations …

Read more »

blue arrows representing a rising share price ASX 200
Share Market News

These 3 ASX 200 shares are topping the volume charts this Friday

Finally, a day of green for ASX shares! The S&P/ASX 200 Index (ASX: XJO) is bouncing back strongly today, after a …

Read more »

Young boy wearing suit and glasses adds up on calculator with coins on table
Share Market News

This world-famous fund manager is ‘buying the dip’. Here’s why

Key points Bill Ackman is one of the most famous fund managers in the world He runs Pershing Square Capital …

Read more »

Two male ASX 200 analysts stand in an office looking at various computer screens showing share prices
Share Market News

ASX 200 (ASX:XJO) midday update: ResMed and PointsBet disappoint

At lunch on Friday, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a much-needed positive …

Read more »

A man activates an arrow shooting up into a cloud sign on his phone, indicating share price movement in ASX tech shares
Share Market News

Is the Betashares Nasdaq 100 ETF (ASX:NDQ) an opportunity in this market correction?

Could the Betashares Nasdaq 100 ETF (ASX: NDQ) be a good opportunity during this correction for both the global share …

Read more »

A woman shouts through a megaphone.
Share Market News

2 ASX growth shares to buy in February with 40% upside

If you’re looking to make some additions to your portfolio in February, then the two ASX shares listed below could …

Read more »

Business woman watching stocks and trends while thinking
Share Market News

5 things to watch on the ASX 200 on Friday

On Thursday, the S&P/ASX 200 Index (ASX: XJO) fought hard and was able to record a small gain. The benchmark index rose …

Read more »